Does surfactant type cause a differential proinflammatory response in preterm infants with respiratory distress syndrome?

Vanessa V. Mercado, Ioana Cristea, Noorjahan Ali, Chauchau Pham, Elizabeth Buescher, Jean Yang, Joie Fisher, Hima Maramreddy, Johanna Calo, Sonya Strassberg, Lance A. Parton

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: The objective of this study was to compare the pulmonary inflammatory response of premature infants with respiratory distress following instillation of one of two commonly available surfactant preparations. Methods: This was a prospective, randomized investigation of preterm infants who were less than 30 weeks of gestational age, weighed less than 1 kg at birth, and who qualified to receive surfactant. Infants with multiple congenital anomalies or whose mothers were taking anti-inflammatory medications were ineligible. Tracheal aspirates (TAs) were collected on days 1, 3, 5, and 7 and airway cytokines from TAs were assayed for interleukin (IL)-8 and IL-6. Results: Infants were evenly matched by gestation (26±2 days and 26±1 days [mean±SD], Surfactant A and B, respectively) and birth weight (730±141 g and 732±167 g). TA cytokine levels were not different between or within groups. Ventilator requirements and clinical outcomes were similar between the two groups. Conclusion: The postnatal airway inflammatory response observed in preterm infants is not altered by the instillation of either surfactant preparation.

Original languageEnglish (US)
Pages (from-to)476-482
Number of pages7
JournalAdvances in Therapy
Volume27
Issue number7
DOIs
StatePublished - Jul 1 2010

Fingerprint

Newborn Respiratory Distress Syndrome
Premature Infants
Surface-Active Agents
Cytokines
Mechanical Ventilators
Interleukin-8
Birth Weight
Gestational Age
Interleukin-6
Anti-Inflammatory Agents
Mothers
Parturition
Pregnancy
Lung

Keywords

  • bronchopulmonary dysplasia
  • cytokine interleukin 6
  • cytokine interleukin 8
  • natural surfactants
  • respiratory distress syndrome
  • tracheal aspirate cytokine

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)

Cite this

Does surfactant type cause a differential proinflammatory response in preterm infants with respiratory distress syndrome? / Mercado, Vanessa V.; Cristea, Ioana; Ali, Noorjahan; Pham, Chauchau; Buescher, Elizabeth; Yang, Jean; Fisher, Joie; Maramreddy, Hima; Calo, Johanna; Strassberg, Sonya; Parton, Lance A.

In: Advances in Therapy, Vol. 27, No. 7, 01.07.2010, p. 476-482.

Research output: Contribution to journalArticle

Mercado, VV, Cristea, I, Ali, N, Pham, C, Buescher, E, Yang, J, Fisher, J, Maramreddy, H, Calo, J, Strassberg, S & Parton, LA 2010, 'Does surfactant type cause a differential proinflammatory response in preterm infants with respiratory distress syndrome?', Advances in Therapy, vol. 27, no. 7, pp. 476-482. https://doi.org/10.1007/s12325-010-0044-3
Mercado, Vanessa V. ; Cristea, Ioana ; Ali, Noorjahan ; Pham, Chauchau ; Buescher, Elizabeth ; Yang, Jean ; Fisher, Joie ; Maramreddy, Hima ; Calo, Johanna ; Strassberg, Sonya ; Parton, Lance A. / Does surfactant type cause a differential proinflammatory response in preterm infants with respiratory distress syndrome?. In: Advances in Therapy. 2010 ; Vol. 27, No. 7. pp. 476-482.
@article{bd67477f5eb14888b935ec3ee06a840d,
title = "Does surfactant type cause a differential proinflammatory response in preterm infants with respiratory distress syndrome?",
abstract = "Introduction: The objective of this study was to compare the pulmonary inflammatory response of premature infants with respiratory distress following instillation of one of two commonly available surfactant preparations. Methods: This was a prospective, randomized investigation of preterm infants who were less than 30 weeks of gestational age, weighed less than 1 kg at birth, and who qualified to receive surfactant. Infants with multiple congenital anomalies or whose mothers were taking anti-inflammatory medications were ineligible. Tracheal aspirates (TAs) were collected on days 1, 3, 5, and 7 and airway cytokines from TAs were assayed for interleukin (IL)-8 and IL-6. Results: Infants were evenly matched by gestation (26±2 days and 26±1 days [mean±SD], Surfactant A and B, respectively) and birth weight (730±141 g and 732±167 g). TA cytokine levels were not different between or within groups. Ventilator requirements and clinical outcomes were similar between the two groups. Conclusion: The postnatal airway inflammatory response observed in preterm infants is not altered by the instillation of either surfactant preparation.",
keywords = "bronchopulmonary dysplasia, cytokine interleukin 6, cytokine interleukin 8, natural surfactants, respiratory distress syndrome, tracheal aspirate cytokine",
author = "Mercado, {Vanessa V.} and Ioana Cristea and Noorjahan Ali and Chauchau Pham and Elizabeth Buescher and Jean Yang and Joie Fisher and Hima Maramreddy and Johanna Calo and Sonya Strassberg and Parton, {Lance A.}",
year = "2010",
month = "7",
day = "1",
doi = "10.1007/s12325-010-0044-3",
language = "English (US)",
volume = "27",
pages = "476--482",
journal = "Advances in Therapy",
issn = "0741-238X",
publisher = "Health Communications Inc.",
number = "7",

}

TY - JOUR

T1 - Does surfactant type cause a differential proinflammatory response in preterm infants with respiratory distress syndrome?

AU - Mercado, Vanessa V.

AU - Cristea, Ioana

AU - Ali, Noorjahan

AU - Pham, Chauchau

AU - Buescher, Elizabeth

AU - Yang, Jean

AU - Fisher, Joie

AU - Maramreddy, Hima

AU - Calo, Johanna

AU - Strassberg, Sonya

AU - Parton, Lance A.

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Introduction: The objective of this study was to compare the pulmonary inflammatory response of premature infants with respiratory distress following instillation of one of two commonly available surfactant preparations. Methods: This was a prospective, randomized investigation of preterm infants who were less than 30 weeks of gestational age, weighed less than 1 kg at birth, and who qualified to receive surfactant. Infants with multiple congenital anomalies or whose mothers were taking anti-inflammatory medications were ineligible. Tracheal aspirates (TAs) were collected on days 1, 3, 5, and 7 and airway cytokines from TAs were assayed for interleukin (IL)-8 and IL-6. Results: Infants were evenly matched by gestation (26±2 days and 26±1 days [mean±SD], Surfactant A and B, respectively) and birth weight (730±141 g and 732±167 g). TA cytokine levels were not different between or within groups. Ventilator requirements and clinical outcomes were similar between the two groups. Conclusion: The postnatal airway inflammatory response observed in preterm infants is not altered by the instillation of either surfactant preparation.

AB - Introduction: The objective of this study was to compare the pulmonary inflammatory response of premature infants with respiratory distress following instillation of one of two commonly available surfactant preparations. Methods: This was a prospective, randomized investigation of preterm infants who were less than 30 weeks of gestational age, weighed less than 1 kg at birth, and who qualified to receive surfactant. Infants with multiple congenital anomalies or whose mothers were taking anti-inflammatory medications were ineligible. Tracheal aspirates (TAs) were collected on days 1, 3, 5, and 7 and airway cytokines from TAs were assayed for interleukin (IL)-8 and IL-6. Results: Infants were evenly matched by gestation (26±2 days and 26±1 days [mean±SD], Surfactant A and B, respectively) and birth weight (730±141 g and 732±167 g). TA cytokine levels were not different between or within groups. Ventilator requirements and clinical outcomes were similar between the two groups. Conclusion: The postnatal airway inflammatory response observed in preterm infants is not altered by the instillation of either surfactant preparation.

KW - bronchopulmonary dysplasia

KW - cytokine interleukin 6

KW - cytokine interleukin 8

KW - natural surfactants

KW - respiratory distress syndrome

KW - tracheal aspirate cytokine

UR - http://www.scopus.com/inward/record.url?scp=77956228962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956228962&partnerID=8YFLogxK

U2 - 10.1007/s12325-010-0044-3

DO - 10.1007/s12325-010-0044-3

M3 - Article

C2 - 20586001

AN - SCOPUS:77956228962

VL - 27

SP - 476

EP - 482

JO - Advances in Therapy

JF - Advances in Therapy

SN - 0741-238X

IS - 7

ER -